Boston Scientific (NYSE:BSX) Shares Up 4% – Time to Buy?

Boston Scientific Corporation (NYSE:BSX)’s stock price traded up 4% during mid-day trading on Monday . The stock traded as high as $48.62 and last traded at $48.7370. 4,676,513 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 18,425,279 shares. The stock had previously closed at $46.84.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a research note on Thursday, May 28th. UBS Group decreased their target price on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $60.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Evercore set a $65.00 price target on shares of Boston Scientific in a research report on Monday, July 6th. Finally, Wells Fargo & Company reduced their price target on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a research note on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Stock Performance

The company’s 50-day moving average price is $46.69 and its two-hundred day moving average price is $56.17. The company has a market cap of $69.64 billion, a P/E ratio of 19.45, a price-to-earnings-growth ratio of 1.12 and a beta of 0.57. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has authorized a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In related news, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Edward J. Ludwig purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 194,522 shares of company stock worth $9,385,210 in the last three months. 0.34% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BSX. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the second quarter valued at approximately $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific in the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific during the 4th quarter worth approximately $26,000. Sfam LLC purchased a new position in Boston Scientific during the 4th quarter worth approximately $29,000. Finally, Cresta Advisors Ltd. acquired a new stake in Boston Scientific during the 4th quarter valued at $33,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.